PT  - JOURNAL ARTICLE
AU  - Karunamuni, Roshan A.
AU  - Huynh-Le, Minh-Phuong
AU  - Fan, Chun C.
AU  - Thompson, Wesley
AU  - Eeles, Rosalind A.
AU  - Kote-Jarai, Zsofia
AU  - Muir, Kenneth
AU  - Lophatananon, Artitaya
AU - UKGPCS collaborators
AU  - Schleutker, Johanna
AU  - Pashayan, Nora
AU  - Batra, Jyotsna
AU - APCB BioResource (Australian Prostate Cancer BioResource)
AU  - Grönberg, Henrik
AU  - Walsh, Eleanor I.
AU  - Turner, Emma L.
AU  - Lane, Athene
AU  - Martin, Richard M.
AU  - Neal, David E.
AU  - Donovan, Jenny L.
AU  - Hamdy, Freddie C.
AU  - Nordestgaard, Børge G.
AU  - Tangen, Catherine M.
AU  - MacInnis, Robert J.
AU  - Wolk, Alicja
AU  - Albanes, Demetrius
AU  - Haiman, Christopher A.
AU  - Travis, Ruth C.
AU  - Stanford, Janet L.
AU  - Mucci, Lorelei A.
AU  - West, Catharine M. L.
AU  - Nielsen, Sune F.
AU  - Kibel, Adam S.
AU  - Wiklund, Fredrik
AU  - Cussenot, Olivier
AU  - Berndt, Sonja I.
AU  - Koutros, Stella
AU  - Sørensen, Karina Dalsgaard
AU  - Cybulski, Cezary
AU  - Grindedal, Eli Marie
AU  - Park, Jong Y.
AU  - Ingles, Sue A.
AU  - Maier, Christiane
AU  - Hamilton, Robert J.
AU  - Rosenstein, Barry S.
AU  - Vega, Ana
AU - The IMPACT Study Steering Committee and Collaborators
AU  - Kogevinas, Manolis
AU  - Penney, Kathryn L.
AU  - Teixeira, Manuel R.
AU  - Brenner, Hermann
AU  - John, Esther M.
AU  - Kaneva, Radka
AU  - Logothetis, Christopher J.
AU  - Neuhausen, Susan L.
AU  - Razack, Azad
AU  - Newcomb, Lisa F.
AU  - PASS Investigators, Canary
AU  - Gamulin, Marija
AU  - Usmani, Nawaid
AU  - Claessens, Frank
AU  - Gago-Dominguez, Manuela
AU  - Townsend, Paul A.
AU  - Roobol, Monique J.
AU  - Zheng, Wei
AU - The Profile Study Steering Committee
AU  - Mills, Ian G.
AU  - Andreassen, Ole A.
AU  - Dale, Anders M.
AU  - Seibert, Tyler M.
AU - The PRACTICAL Consortium
TI  - Additional SNPs improve the performance of a polygenic hazard score for prostate cancer
AID  - 10.1101/2020.09.11.20188383
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.11.20188383
4099  - http://medrxiv.org/content/early/2020/09/15/2020.09.11.20188383.short
4100  - http://medrxiv.org/content/early/2020/09/15/2020.09.11.20188383.full
AB  - Background Polygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).Materials and Method 180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy.Results 166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer.Conclusion Incorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.Competing Interest StatementAll authors declare no personal or financial conflicts of interest for the submitted work except as follows. CCF is a scientific consultant for CorTechs Labs, Inc. RE reports honorarium as a speaker for GU-ASCO meeting in San Francisco Jan 2016, support from Janssen, and honorarium as speaker for RMH-FR meeting Nov 2017. She reports honorarium as a speaker at the University of Chicago invited talk May 2018, and an educational honorarium by Bayer & Ipsen to attend GU Connect Treatment sequencing for mCRPC patients within the changing landscape of mHSPC at ESMO Barcelona, Sep 2019. She reports member of external Expert Committee on the Prostate Dx Advisory Panel. OAA received speaker honorarium from Lundbeck, and is a consultant for Healthlytix. AMD reports that he was a founder and holds equity in CorTechs Labs Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc., and the Mohn Medical Imaging and Visualization Centre. He received funding through research grants from GE Healthcare to UCSD. The terms of these arrangements have been reviewed by and approved by UCSD in accordance with its conflict of interest policies. TMS reports honoraria, outside of the present work, from: University of Rochester, Varian Medical Systems, Multimodal Imaging Servcies Corporation; and WebMD. He reports research funding from NIH/NBIB, U.S. Department of Defense, Radiological Society of North America, American Society for Radiation Oncology, and Varian Medical Systems.Funding StatementThis study was funded in part by a grant from the United States National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (#K08EB026503), the Research Council of Norway (#223273), KG Jebsen Stiftelsen, and South East Norway Health Authority.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All contributing studies were approved by the relevant ethics committees and performed in accordance with the Declaration of Helsinki; written informed consent was obtained from the study participants. The present analyses used de-identified data from the PRACTICAL consortium and have been approved by the review board at the corresponding authors institution.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this work were obtained from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. Readers who are interested in accessing the data must first submit a proposal to the Data Access Committee. If the reader is not a member of the consortium, their concept form must be sponsored by a principal investigator (PI) of one of the PRACTICAL consortium member studies. If approved by the Data Access Committee, PIs within the consortium, each of whom retains ownership of their data submitted to the consortium, can then choose to participate in the specific proposal. In addition, portions of the data are available for request from dbGaP (database of Genotypes and Phenotypes) which is maintained by the National Center for Biotechnology Information (NCBI): https://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostatehttps://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostate. Anyone can apply to join the consortium. The eligibility requirements are listed here: http://practical.icr.ac.uk/blog/?page_id=9. Joining the consortium would not guarantee access, as a proposal for access would still be submitted to the Data Access Committee, but there would be no need for a separate member sponsor. Readers may find information about application by using the contact information below: Rosalind Eeles Principal Investigator for PRACTICAL Professor of Oncogenetics Institute of Cancer Research (ICR) Sutton, UK Email: PRACTICAL@icr.ac.uk URL: http://practical.icr.ac.uk Tel: ++44 (0)20 8722 4094